Gujarat Kidney And Super Speciality Limited Share Price & Analysis
₹142.53▲ +0.20%Updated 13 May 2026, 11:32 am IST
LTP
₹142.53
+0.2%
Open
₹—
High
₹147.8
Low
₹141.1
Close
₹142.53
52W High
₹140
52W Low
₹98.2
Volume
735K
Lot Size
1
Sector
Healthcare
Market Cap
₹1K Cr
Face Value
₹2
Small Cap
Price Chart
Fundamentals
P/E
112
Sector P/E
43.5
P/B
33.54
EPS
₹1.66
ROE
51.2%
ROCE
51.5%
D/E Ratio
0.58
Div Yield
0%
Book Value
₹4.25
+
Strengths
- ✓Excellent return on equity (ROE 51.2%)
- ✓Efficient capital deployment (ROCE 51.5%)
−
Concerns
- ✗Premium to sector peers (P/E 112x vs industry 43.5x)
- ✗High premium to book value (P/B 33.5x)
- ✗Trading near 52-week high (₹140)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,844 | ₹4.4L Cr | 36.5 | 5.69 | 16.9 | 20.2 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,711 | ₹1.8L Cr | 70.3 | 11.55 | 15.4 | 20.4 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,358 | ₹1.5L Cr | 64.3 | 17.43 | 26.5 | 27 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,057 | ₹1.2L Cr | 64.1 | 12.75 | 18.4 | 16.6 | 0.88 |
| CIPLA Cipla Limited | ₹1,306 | ₹1.1L Cr | 22.9 | 3.2 | 17.8 | 22.7 | 0.01 |
| LUPIN Lupin Limited | ₹2,238 | ₹1.1L Cr | 18.9 | 4.56 | 29.1 | 30.3 | 0.32 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,274 | ₹1.1L Cr | 19.4 | 2.95 | 18 | 22.7 | 0.16 |
Showing 7 peers in the same sector · Sorted by market cap
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|
| Revenue | ₹23.25 Cr ▲79.8% | ₹12.93 Cr ▼15.3% | ₹15.26 Cr ▲29.4% | ₹11.79 Cr ▲25.3% | ₹9.41 Cr |
| Op. Profit | ₹6.9 Cr ▲34.8% | ₹5.12 Cr ▼40.6% | ₹8.62 Cr ▲87.4% | ₹4.6 Cr ▼5.3% | ₹4.86 Cr |
| OPM | 29.7% ▼25.1% | 39.6% ▼29.9% | 56.5% ▲44.8% | 39.0% ▼24.5% | 51.6% |
| Net Profit | ₹3.7 Cr ▲28.5% | ₹2.88 Cr ▼46.7% | ₹5.4 Cr ▲113.4% | ₹2.53 Cr ▼14.5% | ₹2.96 Cr |
| EPS (₹) | 0.37 ▼21.3% | 0.47 ▼44.7% | 0.85 ▼94.5% | 15.53 ▼15.6% | 18.39 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Revenue | ₹40.24 Cr ▲743.6% | ₹4.77 Cr | ₹0 Cr |
| Expenses | ₹23.68 Cr ▲742.7% | ₹2.81 Cr ▲28000.0% | ₹0.01 Cr |
| Op. Profit | ₹16.56 Cr ▲744.9% | ₹1.96 Cr ▲19700.0% | ₹-0.01 Cr |
| OPM | 41.1% ▲0.1% | 41.1% | — |
| Other Income | ₹0.15 Cr ▼78.6% | ₹0.7 Cr | ₹0 Cr |
| Interest | ₹0.65 Cr ▲828.6% | ₹0.07 Cr | ₹0 Cr |
| Depreciation | ₹3.29 Cr ▲928.1% | ₹0.32 Cr | ₹0 Cr |
| PBT | ₹12.77 Cr ▲462.6% | ₹2.27 Cr ▲22800.0% | ₹-0.01 Cr |
| Tax % | 25.5% ▲3.5% | 24.7% | 0.0% |
| Net Profit | ₹9.5 Cr ▲455.6% | ₹1.71 Cr ▲17200.0% | ₹-0.01 Cr |
| EPS (₹) | 1.66 ▼98.1% | 85.5 ▲17200.0% | -0.5 |
| Div Payout | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Liabilities | ||||
| Equity Capital | ₹11.37 Cr ▲0.0% | ₹11.37 Cr ▲5585.0% | ₹0.2 Cr ▲0.0% | ₹0.2 Cr |
| Reserves | ₹22.13 Cr ▲51.9% | ₹14.57 Cr ▲37.5% | ₹10.6 Cr ▲6135.3% | ₹0.17 Cr |
| Borrowings | ₹19.53 Cr ▲135.0% | ₹8.31 Cr ▲41.8% | ₹5.86 Cr | ₹0 Cr |
| Other Liabilities | ₹22.65 Cr ▲7.4% | ₹21.09 Cr ▲446.4% | ₹3.86 Cr ▲10.3% | ₹3.5 Cr |
| Total Liabilities | ₹75.68 Cr ▲36.8% | ₹55.34 Cr ▲169.7% | ₹20.52 Cr ▲430.2% | ₹3.87 Cr |
| Assets | ||||
| Fixed Assets | ₹29.43 Cr ▼5.1% | ₹31.01 Cr ▲127.3% | ₹13.64 Cr | ₹0 Cr |
| CWIP | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹46.25 Cr ▲90.1% | ₹24.33 Cr ▲253.6% | ₹6.88 Cr ▲77.8% | ₹3.87 Cr |
| Total Assets | ₹75.68 Cr ▲36.8% | ₹55.34 Cr ▲169.7% | ₹20.52 Cr ▲430.2% | ₹3.87 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Operating CF | ₹13.61 Cr ▲1024.8% | ₹1.21 Cr | ₹0 Cr |
| Investing CF | ₹-18.14 Cr ▼8345.5% | ₹0.22 Cr | ₹0 Cr |
| Financing CF | ₹6.16 Cr ▲1410.6% | ₹-0.47 Cr | ₹0 Cr |
| Net Cash Flow | ₹1.63 Cr ▲68.0% | ₹0.97 Cr | ₹0 Cr |
| Free Cash Flow | ₹-4.64 Cr ▼382.9% | ₹1.64 Cr | ₹0 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Debtor Days | 138d ▼57.2% | 321d | — |
| Inventory Days | — | — | — |
| Days Payable | — | — | — |
| Cash Conv. Cycle | 138d ▼57.2% | 321d | — |
| Working Capital Days | -24d ▼124.1% | 100d | — |
| ROCE | 51.5% ▲167.5% | 19.3% | — |
Source: Screener.in · Lower days = better efficiency
About Gujarat Kidney And Super Speciality Limited
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services.[1]
Healthcare · Healthcare Services
Related Analysis
Frequently Asked Questions
What is Gujarat Kidney And Super Speciality Limited share price today?▾
Gujarat Kidney And Super Speciality Limited (GKSL) is currently trading at ₹142.53 on NSE, up 0.20% as of the last market session. Prices update daily after market close on MarketNetra.
Is Gujarat Kidney And Super Speciality Limited available in F&O (Futures & Options)?▾
Yes, Gujarat Kidney And Super Speciality Limited (GKSL) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Gujarat Kidney And Super Speciality Limited 52-week high and low?▾
Gujarat Kidney And Super Speciality Limited's 52-week high is ₹140 and the 52-week low is ₹98.2. The current price of ₹142.53 is -1.8% below the 52W high.
What is Gujarat Kidney And Super Speciality Limited P/E ratio?▾
Gujarat Kidney And Super Speciality Limited's current P/E ratio is 112. This indicates the market is paying ₹112 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Gujarat Kidney And Super Speciality Limited options?▾
Gujarat Kidney And Super Speciality Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade GKSL options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.